Budget 2023Budget 2023


  • Tata AIA Life Insurance
  • Hafele
  • Motilal Oswal
Live Now : Nifty Banker 3.0 | India's First Retail Index Traders Online Conference.
Budget 2023
Budget 2023
you are here: HomeNewsIndia

Relief for SII as court rejects trademark-violation plea over 'Covishield'

On January 4, Cutis-Biotech filed a suit in the civil court claiming it was a prior user of the brandname Covishield, and sought to restrain SII from using the name.

January 31, 2021 / 08:05 AM IST
(Image: AFP)

(Image: AFP)

A local court has rejected an application seeking injunction against the use of "Covishield" as brandname by the vaccine-maker Serum Institute of India (SII), the company said on Saturday.

SII is producing a coronavirus vaccine named Covishield, co-developed by the University of Oxford and British-Swedish company AstraZeneca. The Indian government has purchased 11 million doses of Covishield vaccine.

While the court order was not available immediately, the lawyer of Cutis-Biotech, which had filed the suit, said it would file an appeal in the high court.

Also read: Inside the world's biggest vaccine factory, India's Serum Institute